Additions and Corrections pubs.acs.org/crystal
Correction to Rare Case of Polymorphism in a Racemic Fluoxetine Nitrate Salt: Phase Behavior and Relative Stability Paulo S. Carvalho, Jr., Javier Ellena,* Dmitry S. Yufit, and Judith A. K. Howard Cryst. Growth Des. 2016, 16(7), 3875−3883. DOI:10.1021/acs.cgd.6b00442. Publication Date (Web): May 12, 2016 In the aforementioned paper, the fluoxetine nitrate crystallized in the space group Pca21 and was described as a kryptoracemate. However, since this is a polar space group and not a Sohcke one,1,2 this classification is not applicable, as has been kindly pointed out by Prof. Dr. Ivan Bernal. We are grateful to Prof. Bernal for his careful reading of our manuscript. Although this new definition does not alter our discussion of the polymorphism discovered, we suggest that in the paper where it is written “kryptoracemate”, this should be understood as a “noncentrosymmetric structure composed of two independent enantiomers in the asymmetric unit”, which is also a rare occurrence. Thus, we emphasize that despite the misnomer, the paper does not fail to describe a rare case of polymorphism.
■
REFERENCES
(1) Bernal, I.; Cai, J.; Massoud, S. S.; Watkins, S. F.; Fronczek, F. R. the Phenomenon of Kryptoracemic Crystallization. Part 1. Counterion Control of Crystallization Pathway Selection. Part 4. the Crystallization Behavior of (±)-[Co(tren)(NO2)2]Br(I), (±)-[Co(tren)(NO2)2]2Br(ClO4)·H2O(II), (+)/(−)-[Co(tren)(NO2)2]ClO4(III) and Attempts to Solve the Structure of (±)-[Co(tren)(NO2)2]NO3(IV). J. Coord. Chem. 1996, 38 (1−2), 165−181. (2) Bernal, I.; Watkins, S. A list of organometallic kryptoracemates. Acta Crystallogr., Sect. C: Struct. Chem. 2015, 71 (3), 216−221.
© XXXX American Chemical Society
A
DOI: 10.1021/acs.cgd.6b01422 Cryst. Growth Des. XXXX, XXX, XXX−XXX
